Ttbio Corp. (6493) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Ttbio Corp. TWD 5.18, price TWD 35.80, upside -85.5%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Ttbio Corp. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.
How to read this chart
10‑month range 21.30 TWD – 55.60 TWD · fair‑value band 3.40 TWD – 6.95 TWD · the 35.80 TWD price screens above the 5.18 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 24, 2026.
Follow Ttbio in your weekly email
Every Wednesday you see whether Ttbio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Ttbio Corp. manufactures, sells, and maintains medical devices under the TTBIO brand name in Taiwan and the United States. The company provides high and low-speed hand piece products, dental spare parts, service rotors, maintenance units, electric hand piece systems, and precision-machined components.
Show more
Ttbio Corp. manufactures, sells, and maintains medical devices under the TTBIO brand name in Taiwan and the United States. The company provides high and low-speed hand piece products, dental spare parts, service rotors, maintenance units, electric hand piece systems, and precision-machined components. It serves various industries, including medical, automotive, aerospace, security, computer components, maintenance parts, and custom machining. Ttbio Corp. was founded in 2012 and is based in Taichung, Taiwan.
Stock analysis
Ttbio Corp. (6493) currently trades at 35.80 TWD, while our model-based Fair Value estimate is 5.18 TWD, 85.5% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 10.27 TWD per share, and 0 of the 5 models we run sit above the 35.80 TWD price.
Bear case: the Dividend Discount group reads lowest at 3.03 TWD, and 5 of the 5 models stay below the price. Evidence for this calculation is low.
Scenario range: 3.40 TWD (bear) to 6.95 TWD (bull), the price of 35.80 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Ttbio Corp. reported revenue of 399M TWD in FY2025 versus 306M TWD in FY2021, a compound +6.9%/yr. Reported net income was −21.3M TWD in FY2025.
Key figures
Market cap 1.2B TWD (≈ $39.0M) · P/S ratio 3.11 · EPS (TTM) −0.7100 TWD · Dividend yield 0.5% · Net margin −5.3% · Return on equity −6.5% · Return on assets (EBIT) 1.2% · Operating margin −12.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at −86%, 6493 screens richer than that median.
Fair Value models
Bear 3.40 TWDFair Value 5.18 TWDBull 6.95 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+27.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.4%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.9%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−7.7% (2020) → −5.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 192 stocks
Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score37 · Bottom 25%
Fair Value upside−85.5% · Bottom 25%
Profitability
Return on assets−2.2% · Bottom 25%
Net margin (TTM)−5.3% · Bottom 25%
Operating margin (TTM)−12.9% · Bottom 25%
Growth and dividend
Revenue growth3.4% · Below median
Dividend yield (TTM)0.5% · Bottom 25%
Balance sheet
Debt / equity0.07× · Below median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/B0.11× · Cheapest 25%
P/S (TTM)0.10× · Cheapest 25%
EV/EBITDA2.4× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 25
FUTURE (revenue growth)17· sector 36
PAST (return on equity)0· sector 28
HEALTH (low debt)96· sector 96
DIVIDEND (yield)10· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Ttbio Corp. Fair Value". https://www.fairvalue-calculator.com/stock/6493
Frequently asked questions
Is Ttbio Corp. (6493) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 5.18 TWD versus a price of 35.80 TWD, about −86% upside (overvalued).
What is the fair value of 6493?
Our model-based fair value for Ttbio Corp. is 5.18 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 35.80 TWD.
What is the quality score of 6493?
Ttbio Corp. has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ttbio Corp. (6493)?
Our model-based price target is the fair value of 5.18 TWD (as of Sep 24, 2026) from 5 valuation models. Cautious scenario 3.40 TWD, optimistic scenario 6.95 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Ttbio Corp. stock forecast for 2026?
Our models put fair value at 5.18 TWD, about −86% upside versus a price of 35.80 TWD (overvalued). Cautious scenario 3.40 TWD, optimistic scenario 6.95 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Ttbio Corp. (6493)?
Ttbio Corp. reported trailing-twelve-month revenue of about 399M TWD (latest available figure, as of Sep 24, 2026).
Does Ttbio Corp. pay a dividend?
Ttbio Corp. currently shows a dividend yield of about 0.49% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Ttbio Corp. (6493)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ttbio Corp. it is 5.18 TWD per share (as of Sep 24, 2026), against a price of 35.80 TWD. It is the blended result of 5 valuation models (cash flow, earnings, asset, dividend).
Is Ttbio Corp. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6493 trades above its calculated fair value: price 35.80 TWD, fair value 5.18 TWD, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6493?
No. The price is what the market pays today (35.80 TWD); the fair value is what the company's own numbers justify (5.18 TWD). For Ttbio Corp. the two are 30.62 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Ttbio Corp. worth?
The market values Ttbio Corp. at about 1.2B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 35.80 TWD; our models calculate a fair value of 5.18 TWD per share.
What do the bullish and bearish scenarios say about 6493?
Our models span a range for Ttbio Corp.: cautious scenario 3.40 TWD, base 5.18 TWD, optimistic 6.95 TWD per share (as of Sep 24, 2026, price 35.80 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ttbio Corp. (6493)?
Balance-sheet figures for Ttbio Corp. (as of Sep 24, 2026): return on equity −6.5%, debt of 0.07 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
Which stocks are comparable to Ttbio Corp.?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ttbio Corp. stock attractive at the current price?
The data as of Sep 24, 2026: price 35.80 TWD, calculated fair value 5.18 TWD (−86%), Quality Score 37/100, from 5 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6493 calculated?
We run Ttbio Corp. through 5 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 5.18 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Ttbio Corp. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ttbio Corp. (6493)?
The closing price on Oct 2, 2026 was 35.80 TWD. Our model-based fair value is 5.18 TWD, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ttbio Corp. right now?
The price sits above even our optimistic bull case (6.95 TWD). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (3.40 TWD to 6.95 TWD) leaves room in how you read the outcome.
Key figures of Ttbio Corp.
How large is the market capitalisation of Ttbio Corp. (6493)?
The market capitalisation of Ttbio Corp. is 1.2B TWD (≈ $39.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ttbio Corp. (6493)?
The price-to-sales ratio of Ttbio Corp. is 3.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ttbio Corp. (6493)?
Earnings per share at Ttbio Corp. are −0.7100 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Ttbio Corp. (6493)?
The dividend yield of Ttbio Corp. is 0.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Ttbio Corp. (6493)?
The net margin of Ttbio Corp. is −5.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ttbio Corp. (6493)?
The return on equity (ROE) of Ttbio Corp. is −6.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ttbio Corp. (6493)?
On an EBIT basis the return on assets of Ttbio Corp. is 1.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ttbio Corp. (6493)?
The operating margin of Ttbio Corp. is −12.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ttbio Corp. (6493)?
Revenue at Ttbio Corp. is growing +3.4% versus a year earlier (3y avg −1.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Ttbio Corp. (6493) generate?
The free cash flow of Ttbio Corp. is −50.0M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Ttbio Corp. (6493) carry?
The net debt of Ttbio Corp. is 58.0M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Ttbio Corp. in the live analysis
One click puts Ttbio Corp. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
